WO2016186346A1 - Oct4가 도입된 인간체세포로부터 직접적 리프로그래밍을 통한 희소돌기아교 전구세포를 유도하는 방법 - Google Patents
Oct4가 도입된 인간체세포로부터 직접적 리프로그래밍을 통한 희소돌기아교 전구세포를 유도하는 방법 Download PDFInfo
- Publication number
- WO2016186346A1 WO2016186346A1 PCT/KR2016/004603 KR2016004603W WO2016186346A1 WO 2016186346 A1 WO2016186346 A1 WO 2016186346A1 KR 2016004603 W KR2016004603 W KR 2016004603W WO 2016186346 A1 WO2016186346 A1 WO 2016186346A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- human somatic
- somatic cells
- oligodendrocyte progenitor
- progenitor cells
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
Definitions
- the present invention relates to a method for inducing oligodendrocyte progenitor cells through direct reprogramming from human somatic cells into which a nucleic acid molecule encoding Oct4 protein is introduced or human somatic cells treated with Oct4 protein.
- oligodendrocyte procursor cells which can differentiate into oligodendrocytes capable of forming myelin sheath, has emerged as a major treatment method. Research into embryonic stem cells and adult stem cells to obtain.
- Embryonic Stem Cells unlike somatic cells, are pluripotentcy cells that can differentiate into any cell in the body that has the ability to divide indefinitely.
- Adult stem cells are multipotency cells that can be extracted from a patient.
- neural stem cells NSC
- Neural stem cells which are adult stem cells, have gained the spotlight as cell therapy products because they have the advantage of overcoming the immune rejection problem when treating neurological diseases, but their ability to differentiate into oligodendrocytes is remarkably low, and the patient's own brain tissue Because of the limited number of cells that can be obtained from the situation is not very effective.
- Embryonic stem cells also have disadvantages that must be overcome for clinical use. First of all, embryonic stem cells have ethical problems because they need to destroy fertilized embryos to obtain embryonic stem cells. There is a problem that rejection occurs.
- dedifferentiation from differentiated cells to undifferentiated cells has been in the spotlight, and dedifferentiation is using pluripotent stem cells such as embryonic stem cells using differentiated cells.
- pluripotent stem cells such as embryonic stem cells using differentiated cells.
- iPS cells induced pluripotent stem cells
- An alternative method of stem cell differentiation is a direct reprogramming method, which is a method of introducing genes that are specifically expressed in cells and grows with a combination of derivatization inducers and low molecular weight substances. It can be seen as two techniques to induce desired cells without obtaining pluripotency through signal regulation. This method is highly regarded for removing many of the factors that inhibit clinical application while having the advantages of several stem cells.
- the present inventors have made intensive efforts to induce rare oligodendrocyte progenitor cells through direct reprogramming from human somatic cells.
- the present inventors introduced Oct4 into human somatic cells and treated several low molecular materials involved in oligodendrocyte formation. It was confirmed that induction into progenitor glial progenitor cells was completed, and the present invention was completed.
- An object of the present invention is oligodendrocyte progenitor cells from human somatic cells through direct reprogramming, comprising culturing human somatic cells into which a nucleic acid molecule encoding Oct4 protein is introduced in a medium containing a specific low molecular weight material.
- Another object of the present invention is direct reprogramming comprising culturing human somatic cells in a medium containing a specific low molecular weight material, wherein the human somatic cells are treated with Oct4 protein before, simultaneously with, or after culturing.
- the present invention provides a method for inducing oligodendrocyte progenitor cells from human somatic cells.
- Another object of the present invention is to provide a oligodendrocyte precursor through direct reprogramming from human somatic cells treated with Oct4 protein or introduced with a nucleic acid molecule encoding Oct4 protein, which contains a specific low molecular weight substance as an active ingredient. It is to provide a composition for cell induction.
- Still another object of the present invention is to provide a method for differentiating oligodendrocyte progenitor cells prepared by the above method into oligodendrocytes.
- the present invention provides a human somatic cell into which a nucleic acid molecule encoding Oct4 protein is introduced (i) a TGF- ⁇ type I receptor inhibitor; (ii) Inhibitor of Rho-associated kinase; (iii) Histone deacetylase inhibitors; And (iv) culturing the oligodendrocyte progenitor cells from human somatic cells through direct reprogramming comprising culturing in a medium containing a Shh agent (Sonic hedgehog agonist).
- the present invention also relates to human somatic cells comprising (i) a TGF- ⁇ type I receptor inhibitor; (ii) Inhibitor of Rho-associated kinase; (iii) Histone deacetylase inhibitors; And (iv) culturing in a medium containing Shh agonist (Sonic hedgehog agonist), wherein the human somatic cells are treated via direct reprogramming, which comprises the step of treating Oct4 protein before, simultaneously with or after culturing.
- Shh agonist Sonic hedgehog agonist
- the invention also relates to (i) TGF- ⁇ type I receptor inhibitors; (ii) Inhibitor of Rho-associated kinase; (iii) Histone deacetylase inhibitors; And (iv) oligodendum through direct reprogramming from human somatic cells into which a nucleic acid molecule encoding Oct4 protein is introduced or human somatic cells treated with Oct4 protein, comprising a Shh agent (Sonic hedgehog agonist) as an active ingredient.
- a composition for inducing glial progenitor cells is provided.
- the present invention also provides a step of culturing the oligodendrocyte progenitor cells prepared by the above method in a medium containing a ROCK inhibitor (Inhibitor of Rho-associated kinase), a calcium channel agonist and a Leukemia Inhibitory Factor (LIF). It provides a method for differentiating oligodendrocyte progenitor cells comprising oligodendrocytes.
- ROCK inhibitor Inhibitor of Rho-associated kinase
- LIF Leukemia Inhibitory Factor
- iOPCs are induced by introducing Oct4 into Fibroblasts differentiated from Sox10 :: eGFP hESCs.
- Figure 2 shows the introduction of Oct4 into Sox10 :: eGFP fibroblasts and incubated in Reprogramming Media (RM) for 7 days, followed by incubation in Inducing Media (IM) to form small molecules required to establish oligodendrocyte progenitor cells (iOPCs). It shows the process of screening sex material.
- RM Reprogramming Media
- IM Inducing Media
- KSR Knockout Serum Replacement
- FIG. 6 compares Sox10 expression in a medium in which low molecular weight substances were removed one by one and in a medium containing all of them.
- KSR Knockout Serum Replacement
- MMET epithelial to epithelial transition
- 11 is a result of comparing the mRNA expression of OPC marker genes in iOPC by real-time PCR.
- oligodendrocyte oligodendrocytes
- oligodendrocyte in the form of a typical branch when the established iOPC cultured for 40 to 60 days in the growth conditions excluding differentiation conditions, real-time PCR and immunochemical staining method It is a result confirming the increased expression of MBP and MAG markers of oligodendrocytes.
- FIG. 13 shows that iOPC expressing GFP is co-cultured with neurons of mice to differentiate into oligodendrocytes, and neurons and myelin myelination are achieved.
- FIG. 14 confirms that myelin is observed similarly to normal mice by implanting iOPC into multiple sclerosis animal models in order to verify the efficacy of differentiation and treatment in vivo.
- FIG. 16 shows the proliferation after removing iFCs and PDGF-AA, which are growth factors of OPCs, from the culture medium to prove that iOPCs are iOPCs that proliferate in response to growth factors without passing through neural stem cells.
- iOPCs are iOPCs that proliferate in response to growth factors without passing through neural stem cells.
- Expression of OPC markers PDGFRa, A2B5 in the growth factor dependent proliferating cells was confirmed by FACS analysis.
- FIG. 17 shows the results of overexpressing Oct4 in hair follicle cells (Hair-follicle Dermal Papilla) and culturing in IM, and analyzing the expression of OPC markers by FACS analysis, real-time PCR, and immunochemical staining.
- FIG. 18 shows the results of overexpressing Oct4 in amniotic stem cells, adipose derived stem cells and skin cells of various ages, and culturing in IM, followed by real-time PCR or FACS analysis of OPC marker expression.
- 19 is a schematic diagram showing the overall contents of the present invention and the difference from the existing technology.
- oligodendrocyte progenitor cells induction into oligodendrocyte progenitor cells through the introduction and control of culture conditions of the Oct4 gene overexpressing Oct4 in human somatic cells and treating various low molecular materials involved in the formation of oligodendrocytes.
- OPC marker gene expression, epigenetics and myelin formation ability in vitro were confirmed.
- the oligodendrocyte progenitor cells thus induced showed differentiation efficacy as a cell therapeutic agent.
- the present invention relates to the development of patient-specific cell therapy using a direct reprogramming method.
- the low molecular weight material KR 10-1357402
- the present inventors have discovered a combination of new substances and a combination with genes. Through this, oligodendrocyte progenitor cells were established without passing neural stem cells from human somatic cells.
- oligodendrocytes after introducing Oct4 gene into the foreskin fibroblasts, which are human somatic cells, oligodendrocytes by culturing in a medium containing A83-01, thiazobibin, effervescent acid (VPA), permophamine and forskolin Progenitor marker expression was confirmed and induction of oligodendrocyte progenitor cells from human somatic cells was confirmed.
- the present invention provides a human somatic cell into which a nucleic acid molecule encoding Oct4 protein is introduced at an integrated point (i) a TGF- ⁇ type I receptor inhibitor; (ii) Inhibitor of Rho-associated kinase; (iii) Histone deacetylase inhibitors; And (iv) culturing the oligodendrocyte progenitor cells from human somatic cells through direct reprogramming comprising culturing in a medium containing a Shh agent (Sonic hedgehog agonist).
- the gene of the nucleic acid form encoding Oct4 protein was introduced into the foreskin fibroblasts, which are human somatic cells, but Oct4 was overexpressed. It can also be used by treating directly to somatic cells. Oct4 protein may be treated before, simultaneously with or after culturing somatic cells in a medium containing low molecular weight material.
- the present invention provides human somatic cells comprising (i) a TGF- ⁇ type I receptor inhibitor; (ii) Inhibitor of Rho-associated kinase; (iii) Histone deacetylase inhibitors; And (iv) culturing in a medium containing Shh agonist (Sonic hedgehog agonist), wherein the human somatic cells are treated via direct reprogramming, which comprises the step of treating Oct4 protein before, simultaneously with or after culturing.
- Shh agonist Sonic hedgehog agonist
- the medium preferably further contains a calcium channel agonist, and also RG108, BIX01294, SP600125, Lysophosphatidic acid, Bayk8644, Forskolin, and dexamethasone.
- a calcium channel agonist preferably further contains any one selected from the group consisting of, but is not limited thereto.
- the TGF- ⁇ type I receptor inhibitor is A83-01
- the ROCK inhibitor is thiazovivin
- the histone deacetylase inhibitor is Valproic Acid
- the Shh agonist is Permorphamine (Purmorphamine).
- the calcium channel agonist is, but is not limited to, Forskolin.
- TGF- ⁇ type I Transforming growth factor- ⁇ type I
- TGF- ⁇ type I Transforming growth factor- ⁇ type I
- TGF- ⁇ type I is a multifunctional peptide that has various functions on cell proliferation, differentiation and various cell types. It is known to play a pivotal role in the growth and differentiation of various tissues such as cell differentiation and to inhibit the proliferation of neural stem cells.
- TGF- ⁇ type I receptor inhibitor A83-01 In addition to the TGF- ⁇ type I receptor inhibitor A83-01, all TGF- ⁇ type I receptor inhibitors including SB432542 may be used, and the low molecular weight TGF- ⁇ type I receptor inhibitor A83-01 may be purchased or used on the market. Can be used to promote neural stem cell proliferation by the inhibitor treatment.
- the TGF- ⁇ type I receptor inhibitor A83-01 is treated in the medium to be included in an effective concentration. Effective concentrations may be affected by factors well known in the art, such as media type and culture method.
- Thiazovivin N-benzyl-2- (pyrimidin-4-ylamino) thiazole-4-carboxamide
- Rho / ROCK Rho / ROCK signal inducing apoptosis of neurons and neural stem cells and neural stem cells. It is known to block PTEN signaling, which inhibits the proliferation of cells, and is expected to inhibit neural stem cell apoptosis, increase self-renewal and self-proliferation (Matthias Groszer, et al., Science 294: 2186, 2001) .
- the thiazovivin is a substance that selectively inhibits ROCK (Rho-associated kinase) as an inhibitor of Rho-associated kinase (ROCK), and Y-27632 may be used in addition to thiazovivin. . Treating the thiazobibin in the medium to be included in an effective concentration, the effective concentration may be affected depending on factors well known in the art, such as the type and culture method of the medium.
- VPN valproic acid, 2-propylpentanoic acid
- valproic acid valproic acid, 2-propylpentanoic acid
- chromatin a substance that inhibits histone deacetylase, and makes chromatin into a high acetylation state, and expression of genes necessary for cell proliferation inhibitors and differentiation. Promotes differentiation of cells (cancer cells), inhibits angiogenesis, and locks the cell cycle to the G1 state to induce apoptosis of cancer cells, resulting in strong cytostatic anti-cancer It is known to exhibit activity.
- Histone deacetylase inhibits gene transcription via pRB / E2F, and the destruction of histone acetylation is associated with a number of cancer developments, and HDAC is associated with hypoxia, mortgage ( Iii) HDAC is known to be recognized as an important regulator of cell carcinogenesis and differentiation by inhibiting the expression of cell proliferation factor and expressing it under severe environmental conditions such as cell carcinogenesis.
- the VPA is known to cause inositol reduction, inhibit GSK-3 ⁇ , activate the ERK pathway, and stimulate PPAR activity.
- HDAC inhibitor histone deacetylase inhibitor
- VPA valproic acid, 2-propylpentanoic acid
- TSA trachostatin
- the derivative may be variously pharmaceutically acceptable.
- Inorganic or organic salts If the treatment concentration is too low, it will be difficult to see the effect. If the concentration is too high, it will be toxic, so it is necessary to check the appropriate concentration according to the cell type.
- purmorphamine is a purine compound, and is known to be involved in the Shh signaling system.
- the permopamine is not particularly limited as long as it can induce the Shh signal, and various derivatives may be used.
- 2- (1-Naphthoxy) -6- (4-morpholinoanilino) -9-cyclohexylpurin) can be purchased commercially.
- the permophamine may be treated with a medium commonly used to induce differentiation into neural stem cell-like cells. This treatment of Shh analogs, permophamine, there is an advantage that does not need to introduce a gene to produce neural stem cells from human fibroblasts.
- the permophamine is included in the medium at an effective concentration. Effective concentrations of permopamine may be affected by factors well known in the art, such as media type and culture method.
- phospholine acts to directly activate the catalytic subunit of dadenylate cyclase to increase the concentration of cAMP in the cell
- trimenypromine is an enzyme that normally degrades norepinephrine at the nerve endings. It acts to inhibit phosphorus monoamine oxidase (MAO).
- the culture medium includes all media commonly used for culturing neural stem cells, and the medium used for culturing generally includes a carbon source, a nitrogen source, and a trace element component.
- the medium of the present invention is DMEM including N2, B27, penicillin / streptomycin, non-essential amino acid, bFGF, PDGF and ascorbic acid, but is not limited thereto.
- the medium for induced cell culture of the present invention can be used without limitation, basal medium known in the art.
- the basal medium may be prepared by artificially synthesizing, or a commercially prepared medium may be used.
- commercially prepared media include Dulbecco's Modified Eagle's Medium (DMEM), Minimal Essential Medium (MEM), Basic Medium Eagle (BME), RPMI 1640, F-10, F-12, ⁇ -MEM ( ⁇ -Minimal). essential medium), G-MEM (Glasgow's Minimal Essential Medium), and Isocove's Modified Dulbecco's Medium, but are not limited thereto.
- DMEM Dulbecco's Modified Eagle's Medium
- MEM Minimal Essential Medium
- BME Basic Medium Eagle
- RPMI 1640 F-10, F-12
- ⁇ -MEM ⁇ -Minimal
- essential medium G-MEM (Glasgow's Minimal Essential Medium)
- the human somatic cells are foreskin fibroblasts, hair follicle dermal papilla, IMR90 pulmonary fibroblasts or dermal fibroblasts, but is not limited thereto. .
- induction of oligodendrocyte precursor cells from amniotic stem cells (Amniotic derived Stem Cells) or Adipose-derived Stem Cells (Aldipose-derived Stem Cells) is also possible.
- Oct4 of the present invention is preferably provided in the form of a protein or nucleic acid encoding a protein thereof, the Oct4 protein of the present invention includes a variant of the Oct4 protein as well as a protein having its wild type amino acid sequence.
- the variant of Oct4 protein refers to a protein in which the native amino acid sequence of Oct4 and one or more amino acid residues have different sequences by deletion, insertion, non-conservative or conservative substitution, or a combination thereof.
- the variant may be a functional equivalent that exhibits the same biological activity as a natural protein, or may be a variant in which the physicochemical properties of the protein are modified as necessary to increase structural stability to a physical and chemical environment or to increase physiological activity.
- nucleic acid having a nucleotide sequence encoding Oct4 protein wherein the nucleotide sequence encoding Oct4 is a nucleotide sequence encoding a wild type or Oct4 protein of the variant form, wherein one or more bases are substituted or deleted. It can be mutated by insertion, insertion, or a combination thereof and can be isolated from nature or prepared using chemical synthesis. Nucleic acid having a nucleotide sequence encoding the Oct4 protein may be a single or double chain, DNA molecules (genome, cDNA) or RNA molecules.
- the nucleic acid encoding the Oct4 protein can be introduced into cells in a manner known in the art, for example, as naked DNA in the form of a vector (Wolff et al. Science , 1990: Wolffet al. J Cell Sci . 103: 1249-59, 1992), liposomes, cationic polymers (Cationic polymer) and the like can be introduced into the cell.
- Liposomes are phospholipid membranes prepared by mixing cationic phospholipids such as DOTMA or DOTAP for gene introduction. When liposomes and anionic nucleic acids are mixed in a proportion, a nucleic acid-liposomal complex is formed.
- vector refers to a gene construct, which is an expression vector capable of expressing a protein of interest in a suitable host cell, and which contains essential regulatory elements operably linked to express the gene insert.
- operably linked refers to a functional linkage of a nucleic acid expression control sequence and a nucleic acid sequence encoding a protein of interest to perform a general function. Operative linkage with recombinant vectors can be prepared using genetic recombination techniques well known in the art, and site-specific DNA cleavage and ligation uses enzymes commonly known in the art and the like.
- Vectors of the present invention include signal or leader sequences for membrane targeting or secretion in addition to expression control elements such as promoters, operators, initiation codons, termination codons, polyadenylation signals, enhancers, and can be prepared in various ways depending on the purpose.
- the promoter of the vector may be constitutive or inducible.
- the expression vector includes a selectable marker for selecting a host cell containing the vector and, in the case of a replicable expression vector, a replication origin. Vectors can self replicate or integrate into host DNA.
- Vectors include plasmid vectors, cosmid vectors, viral vectors, and the like. Preferably, it is a viral vector.
- Viral vectors are retroviruses such as Human immunodeficiency virus (HIV), Murineleukemia virus (MLV), Avian sarcoma / leukosis (ASLV), Spleen necrosis virus (SNV), Rus sarcoma virus (RSV), and Mouse (MMTV).
- mammary tumor virus such as, but not limited to, adenovirus (Adenovirus), adeno-associated virus (Adenoassociated virus), herpes simplex virus (Herpes simplex virus) and the like.
- the rare oligodendrocyte progenitor cells may be characterized by expressing any one or more markers selected from the group consisting of PDGFRa, A2B5, Olig2, Sox10, S100b and ZFP536, Sox1, Sox2 and Pax6 markers It may be characterized by not expressing.
- the present invention provides a kit comprising: (i) a TGF- ⁇ type I receptor inhibitor; (ii) Inhibitor of Rho-associated kinase; (iii) Histone deacetylase inhibitors; And (iv) oligodendum through direct reprogramming from human somatic cells into which a nucleic acid molecule encoding Oct4 protein is introduced or human somatic cells treated with Oct4 protein, comprising a Shh agent (Sonic hedgehog agonist) as an active ingredient. It relates to a composition for inducing glial progenitor cells.
- a calcium channel agonist RG108, BIX01294, SP600125, Lysophosphatidic acid (Lysophosphatidic acid), Bayk8644, Forskolin (Forskolin) It may be characterized by further containing any one selected from the group consisting of, dexamethasone (Dexamethasone), EX527 and Rolipram (Rolipram).
- the TGF- ⁇ type I receptor inhibitor is A83-01
- the ROCK inhibitor is thiazovivin
- the histone deacetylase inhibitor is Valproic Acid
- the Shh agonist is Permorphamine (Purmorphamine).
- the calcium channel agonist is, but is not limited to, Forskolin.
- the oligodendrocyte progenitor cells may be characterized in that they do not express Sox1, Sox2 and Pax6 markers.
- the growth factor and the specific low molecular weight material were removed from the conventional induction culture, and the T3 (triiodo-l-thyronine), induced by using a differentiation medium added with triazobibin, foscholine, and LIF It was confirmed that oligodendrocyte progenitor cells differentiate into oligodendrocytes.
- the present invention provides a rare oligodendrocyte progenitor cell prepared by the above method in which the ROCK inhibitor (Inhibitor of Rho-associated kinase), Calcium channel agonist and LIF (Leukemia Inhibitory Factor) are included. It relates to a method of differentiating oligodendrocyte progenitor cells into oligodendrocytes comprising culturing in a medium.
- ROCK inhibitor Inhibitor of Rho-associated kinase
- Calcium channel agonist and LIF (Leukemia Inhibitory Factor
- the medium is preferably, but not limited to, DMEM containing N2, B27, penicillin / streptomycin, non-essential amino acid, ascorbic acid and T3 (triiodo-l-thyronine).
- the rare oligodendrocyte progenitor cells of the present invention are known to have extremely small amounts in the cerebrum and are known to have low differentiation rate in neural stem cells constituting the cerebrum, thereby establishing many oligodendrocyte progenitor cells from higher stem cells. There is difficulty. Therefore, in the prior art, many studies have been conducted to efficiently establish oligodendrocyte progenitor cells, but there is a problem in that oligodendrocyte progenitor cells can be established through long-term differentiation of at least 70 days.
- the present invention can solve these problems with high efficiency cell conversion rate in a short period of time because the oligodendrocyte progenitor cells can be established through a relatively short-term culture of 1 to 2 weeks through direct reprogramming without neural stem cells. .
- the low molecular material of the present invention is used to treat the nervous system It is expected to play an important role in.
- Demyelination disease is a refractory neurological disease caused by the absence of oligodendrocytes.
- the conventional technique is mostly to establish and treat oligodendrocyte progenitor cells from embryonic stem cells.
- embryonic stem cells have limitations due to immunorejection reactions and have ethical problems, making it difficult to establish them as therapeutic agents.
- the method for establishing oligodendrocyte progenitor cells through direct reprogramming from somatic cells according to the present invention not only solves ethical problems, but can greatly contribute to establishing a patient-specific cell therapeutic agent because there is no immune rejection reaction.
- the present inventors have established conditions for inducing neural stem cells from mouse cells with only low molecular weight materials without gene introduction (KR 10-1357402). Therefore, the Sox10 reporter system, a gene known to be important for the development of oligodendrocytes, was established to establish new conditions for inducing human somatic cells into oligodendrocyte progenitor cells based on the low molecular weight material established in previous studies. :: eGFP) was used to select low molecular weight material (FIG. 1).
- RM Reprogramming Media
- DMEM High Glucose + 5% Knock out Serum Replacement (KSR) + 1% Penicillin / Streptomycin + 1% Non-Essential Amino Acid + basic FGF (bFGF) 20ng / ml + Human Recombinant
- KSR Knock out Serum Replacement
- bFGF basic FGF
- PDGF Platelet Derived Growth Factor
- MET Mesenchymal to Epithelial Transition
- the cells are passaged in a Matrigel coated dish, followed by A83-01, a combination of low-molecular substances that can induce neural stem cells, Thiazovivin, Valproic Acid and Permo.
- Cultures containing Purmorphamine DMEM High glucose + 1X N2 + 1X B27 (without vitamin A) + 1% penicillin / streptomycin + 1% non-essential amino acid + basic FGF (bFGF) 20ng / ml + Human Recombinant Platelet Derived Epigenetic modulator (20) Growth Factor (PDGF) 20 ng / ml + Ascorbic Acid 50 ⁇ g / ml +0.5 ⁇ M A83-01 +0.5 ⁇ M Tazobibin +0.1 mM effervescent acid (VPA) +0.5 ⁇ M permophamine) ) And low molecular weight substances that affect the development of the nervous system.
- the following shows the combination conditions of the low molecular weight materials.
- ATVP 0.5 ⁇ M A83-01 + 0.5 ⁇ M thiazobibin + 0.1 mM effervescent acid (VPA) + 0.5 ⁇ M permophamine, RG108: 0.5 ⁇ M RG108, BIX01294: 0.25 ⁇ M BIX01294, SP600125: 2 ⁇ M SP600125, LPA: 2 ⁇ M lisophospha Lysophosphatidic acid, Bayk: 2 ⁇ M Bayk8644, Fsk: 10 ⁇ M Forskolin, Dex: 1 ⁇ M Dexamethasone, EX527: 5 ⁇ M EX527, Rolipram: 2 ⁇ M Rolipram
- KSR Knockout Serum Replacement contained in Reprogramming Media (RM) of Example 1-1 has been reported to be converted to neural stem cells when used with overexpression of Oct4.
- oligodendrocyte progenitor cells were induced under conditions other than KSR, and it was confirmed that the appearance of oligodendrocyte progenitor cells appeared.
- the low molecular weight material was removed and processed one by one under the induction conditions of Example 1-1, and the highest Sox10 expression was confirmed in the medium containing all the low molecular weight material. 6).
- Sox10 used as reporter cell lines of Example 1-1 are cells obtained through differentiation from ES cells, and thus, stem cells other than fibroblasts cannot be completely excluded. It is not a direct reprogramming from somatic cells.
- the US Shengding team and Mickie Bhatia team used a culture solution containing Knock Out Serum Replacement (KSR) in the process of establishing neural stem cells after overexpressing Oct4 in human body cells.
- KSR Knock Out Serum Replacement
- Reprogramming Media (RM) containing KSR was not used to induce direct reprogramming from human somatic cells without passing neural stem cells, the upper stem cells of oligodendrocyte progenitor cells (FIG. 7).
- the Oct4 gene was introduced into BJ cells, followed by subculture in a Matrigel coated dish, and cultured for 4 days under induction conditions (IM) of the oligodendrocyte progenitor cells established in Examples 1-2.
- IM induction conditions
- MET epithelial-mesenchymal transition
- induced oligodendrocyte progenitor cells induced OPC: iOPC
- Example 3 Differentiation of oligodendrocyte progenitor cells into oligodendrocytes
- the oligodendrocyte progenitor cells induced in Example 2 were implanted into an Experimental Autoimmune Encephalomyelitis mouse model (EAE mouse model).
- induced oligodendrocyte progenitor cells induced OPC: iOPC were differentiated in vivo to show the efficacy as a cell therapy.
- Example 4 Induction of oligodendrocyte progenitor cells via direct reprogramming
- the gene expression change during the 7 days of induction was performed by real-time PCR to verify that iOPC was established by direct reprogramming rather than differentiated from neural stem cells induced after Oct4 overexpression. It was confirmed through.
- iOPC could prove that oligodendrocyte progenitor cells are established through direct reprogramming without neural stem cells for 7 days after induction.
- Example 5 Induction of oligodendrocyte progenitor cells from various human somatic cells
- oligodendrocyte precursor cells Five different cells (Hair-follicle dermal papilla, Amniotic stem cells) were used to determine whether induction of oligodendrocyte precursor cells is possible not only in Foreskin fibroblast but also in other human somatic cells.
- Stem Cells Stem Cells
- IMR90 pulmonary fibroblasts Dermal Fibroblasts
- Adipose-derived Stem Cells were overexpressed in Oct4 and induced into oligodendrocyte progenitor cells.
- PDGFR ⁇ , A2B5 and Olig2 which are representative markers of oligodendrocyte progenitor cells as well as forskin fibroblasts, were confirmed by RT-PCR, immunochemical staining and FACS analysis (FIGS. 17 and 18).
- Oct4 and the low molecular weight combination proved to be an induction method that can be applied to various human somatic cells, not the induction method limited to BJ cells.
- the method of inducing rare oligodendrocyte progenitor cells by treating a low molecular material to Oct4-overexpressed human cells can establish oligodendrocyte progenitor cells with high efficiency for a short period of time through direct reprogramming without neural stem cells. It is useful as a cell therapy for intractable demyelinating diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (19)
- Oct4 단백질을 코딩하는 핵산분자가 도입된 인간 체세포를 (i) TGF-β 타입 I 수용체 억제제 (TGF-β type I receptor inhibitor); (ii) ROCK 억제제 (Inhibitor of Rho-associated kinase); (iii) 히스톤 탈아세틸효소 억제제 (Histone deacetylase inhibitor); 및 (iv) Shh 작용제 (Sonic hedgehog agonist)를 함유하는 배지에서 배양하는 단계를 포함하는 직접적 리프로그래밍 (direct reprogramming)을 통한 인간 체세포로부터 희소돌기아교 전구세포를 유도하는 방법.
- 제1항에 있어서, 상기 배지는 칼슘 통로 작용제 (Calcium channel agonist)를 추가로 함유하는 것을 특징으로 하는 직접적 리프로그래밍 (direct reprogramming)을 통한 인간 체세포로부터 희소돌기아교 전구세포를 유도하는 방법.
- 인간 체세포를 (i) TGF-β 타입 I 수용체 억제제 (TGF-β type I receptor inhibitor); (ii) ROCK 억제제 (Inhibitor of Rho-associated kinase); (iii) 히스톤 탈아세틸효소 억제제 (Histone deacetylase inhibitor); 및 (iv) Shh 작용제 (Sonic hedgehog agonist)를 함유하는 배지에서 배양하되, 상기 인간 체세포는 배양 전, 배양과 동시에 또는 배양 후에 Oct4 단백질을 처리하는 단계를 포함하는 직접적 리프로그래밍 (direct reprogramming)을 통한 인간 체세포로부터 희소돌기아교 전구세포를 유도하는 방법.
- 제3항에 있어서, 상기 배지는 칼슘 통로 작용제 (Calcium channel agonist)를 추가로 함유하는 것을 특징으로 하는 직접적 리프로그래밍 (direct reprogramming)을 통한 인간 체세포로부터 희소돌기아교 전구세포를 유도하는 방법.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 배지는 RG108, BIX01294, SP600125, 리소포스파디드산(Lysophosphatidic acid), Bayk8644, 포스콜린(Forskolin), 덱사메타손(Dexamethasone), EX527 및 로리프램(Rolipram)으로 구성되는 군에서 선택된 어느 하나를 추가로 함유하는 것을 특징으로 하는 직접적 리프로그래밍 (direct reprogramming)을 통한 인간 체세포로부터 희소돌기아교 전구세포를 유도하는 방법.
- 제1항 또는 제3항에 있어서, TGF-β 타입 I 수용체 억제제는 A83-01이고, ROCK 억제제는 티아조비빈 (Thiazovivin)이며, 히스톤 탈아세틸효소 억제제는 발포릭산 (Valproic Acid)이고, Shh 작용제는 퍼모파민 (Purmorphamine)인 것을 특징으로 하는 직접적 리프로그래밍 (direct reprogramming)을 통한 인간 체세포로부터 희소돌기아교 전구세포를 유도하는 방법.
- 제2항 또는 제4항에 있어서, 칼슘 통로 작용제는 포스콜린 (Forskolin)인 것을 특징으로 하는 직접적 리프로그래밍 (direct reprogramming)을 통한 인간 체세포로부터 희소돌기아교 전구세포를 유도하는 방법.
- 제1항 또는 제3항에 있어서, 상기 배지는 N2, B27, 페니실린/스트렙토마이신, 비필수아미노산, bFGF, PDGF 및 아스코브산이 포함된 DMEM인 것을 특징으로 하는 직접적 리프로그래밍 (direct reprogramming)을 통한 인간 체세포로부터 희소돌기아교 전구세포를 유도하는 방법.
- 제1항 또는 제3항에 있어서, 상기 인간 체세포는 포피 섬유아세포 (Foreskin fibroblast), 모낭 모유두세포 (Hair-follicle dermal papilla), IMR90 폐섬유아세포 및 피부 섬유아세포 (Dermal Fibroblasts)로 이루어진 군에서 선택되는 것을 특징으로 하는 직접적 리프로그래밍 (direct reprogramming)을 통한 인간 체세포로부터 희소돌기아교 전구세포를 유도하는 방법.
- 제1항 또는 제3항에 있어서, 상기 희소돌기아교 전구세포는 PDGFRa, A2B5, Olig2, Sox10, S100b 및 ZFP536로 이루어진 군에서 선택되는 어느 하나 이상의 마커를 발현하는 것을 특징으로 하는 직접적 리프로그래밍 (direct reprogramming)을 통한 인간 체세포로부터 희소돌기아교 전구세포를 유도하는 방법.
- 제1항 또는 제3항에 있어서, 상기 희소돌기아교 전구세포는 Sox1, Sox2 및 Pax6 마커를 발현하지 않는 것을 특징으로 하는 직접적 리프로그래밍 (direct reprogramming)을 통한 인간 체세포로부터 희소돌기아교 전구세포를 유도하는 방법.
- (i) TGF-β 타입 I 수용체 억제제 (TGF-β type I receptor inhibitor); (ii) ROCK 억제제 (Inhibitor of Rho-associated kinase); (iii) 히스톤 탈아세틸효소 억제제 (Histone deacetylase inhibitor); 및 (iv) Shh 작용제 (Sonic hedgehog agonist)를 유효성분으로 포함하는, Oct4 단백질을 코딩하는 핵산분자가 도입된 인간 체세포 또는 Oct4 단백질로 처리된 인간 체세포로부터 직접적 리프로그래밍 (direct reprogramming)을 통한 희소돌기아교 전구세포 유도용 조성물.
- 제12항에 있어서, 칼슘 통로 작용제 (Calcium channel agonist)를 추가로 함유하는 것을 특징으로 하는 Oct4 단백질을 코딩하는 핵산분자가 도입된 인간 체세포 또는 Oct4 단백질로 처리된 인간 체세포로부터 직접적 리프로그래밍 (direct reprogramming)을 통한 희소돌기아교 전구세포 유도용 조성물.
- 제12항 또는 제13항에 있어서, RG108, BIX01294, SP600125, 리소포스파디드산(Lysophosphatidic acid), Bayk8644, 포스콜린(Forskolin), 덱사메타손(Dexamethasone), EX527 및 로리프램(Rolipram)으로 구성되는 군에서 선택된 어느 하나를 추가로 함유하는 것을 특징으로 하는 Oct4 단백질을 코딩하는 핵산분자가 도입된 인간 체세포 또는 Oct4 단백질로 처리된 인간 체세포로부터 직접적 리프로그래밍 (direct reprogramming)을 통한 희소돌기아교 전구세포 유도용 조성물.
- 제12항에 있어서, TGF-β 타입 I 수용체 억제제는 A83-01이고, ROCK 억제제는 티아조비빈 (Thiazovivin)이며, 히스톤 탈아세틸효소 억제제는 발포릭산 (Valproic Acid)이고, Shh 작용제는 퍼모파민 (Purmorphamine)인 것을 특징으로 하는 Oct4 단백질을 코딩하는 핵산분자가 도입된 인간 체세포 또는 Oct4 단백질로 처리된 인간 체세포로부터 직접적 리프로그래밍 (direct reprogramming)을 통한 희소돌기아교 전구세포 유도용 조성물.
- 제13항에 있어서, 칼슘 통로 작용제는 포스콜린 (Forskolin)인 것을 특징으로 하는 Oct4 단백질을 코딩하는 핵산분자가 도입된 인간 체세포 또는 Oct4 단백질로 처리된 인간 체세포로부터 직접적 리프로그래밍 (direct reprogramming)을 통한 희소돌기아교 전구세포 유도용 조성물.
- 제12항에 있어서, 상기 희소돌기아교 전구세포는 Sox1, Sox2 및 Pax6 마커를 발현하지 않는 것을 특징으로 하는 Oct4 단백질을 코딩하는 핵산분자가 도입된 인간 체세포 또는 Oct4 단백질로 처리된 인간 체세포로부터 직접적 리프로그래밍 (direct reprogramming)을 통한 희소돌기아교 전구세포 유도용 조성물.
- 제1항 내지 제4항 중 어느 한 항의 방법으로 제조된 희소돌기아교 전구세포를 ROCK 억제제 (Inhibitor of Rho-associated kinase), 칼슘 통로 작용제 (Calcium channel agonist) 및 LIF (Leukemia Inhibitory Factor)가 포함된 배지에서 배양하는 단계를 포함하는 희소돌기아교 전구세포를 희소돌기아교세포로 분화시키는 방법.
- 제18항에 있어서, 상기 배지는 N2, B27, 페니실린/스트렙토마이신, 비필수아미노산, 아스코브산 및 T3 (triiodo-l-thyronine)가 포함된 DMEM인 것을 특징으로 하는 희소돌기아교 전구세포를 희소돌기아교세포로 분화시키는 방법.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16796673.8A EP3321354A4 (en) | 2015-05-19 | 2016-05-02 | Method for inducing oligodendrocyte precursor cells from oct4-induced human somatic cells through direct reprogramming |
AU2016264166A AU2016264166B2 (en) | 2015-05-19 | 2016-05-02 | Method of inducing oligodendrocyte precursor cells from oct4 introduced human somatic cells through direct reprogramming |
CA2986368A CA2986368C (en) | 2015-05-19 | 2016-05-02 | Method of inducing oligodendrocyte precursor cells from oct4-induced human somatic cells through direct reprogramming |
JP2017560793A JP6522790B2 (ja) | 2015-05-19 | 2016-05-02 | Oct4が導入されたヒト体細胞からダイレクトリプログラミングを用いた希突起膠前駆細胞を誘導する方法 |
US15/575,369 US20180155685A1 (en) | 2015-05-19 | 2016-05-02 | Method for inducing oligodendrocyte precursor cells from oct4-induced human somatic cells through direct reprogramming |
CN201680038355.7A CN107810268B (zh) | 2015-05-19 | 2016-05-02 | 通过直接重编程由引入Oct4的人体细胞诱导少突胶质细胞前体细胞的方法 |
US16/429,062 US10767163B2 (en) | 2015-05-19 | 2019-06-03 | Method for inducing oligodendrocyte precursor cells from Oct4-induced human somatic cells through direct reprogramming |
US16/992,136 US11572540B2 (en) | 2015-05-19 | 2020-08-13 | Method for inducing oligodendrocyte precursor cells from OCT4-induced human somatic cells through direct reprogramming |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2015-0069696 | 2015-05-19 | ||
KR20150069696 | 2015-05-19 | ||
KR1020160043593A KR101782488B1 (ko) | 2015-05-19 | 2016-04-08 | Oct4가 도입된 인간체세포로부터 직접적 리프로그래밍을 통한 희소돌기아교 전구세포를 유도하는 방법 |
KR10-2016-0043593 | 2016-04-08 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/575,369 A-371-Of-International US20180155685A1 (en) | 2015-05-19 | 2016-05-02 | Method for inducing oligodendrocyte precursor cells from oct4-induced human somatic cells through direct reprogramming |
US16/429,062 Division US10767163B2 (en) | 2015-05-19 | 2019-06-03 | Method for inducing oligodendrocyte precursor cells from Oct4-induced human somatic cells through direct reprogramming |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016186346A1 true WO2016186346A1 (ko) | 2016-11-24 |
Family
ID=57320506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/004603 WO2016186346A1 (ko) | 2015-05-19 | 2016-05-02 | Oct4가 도입된 인간체세포로부터 직접적 리프로그래밍을 통한 희소돌기아교 전구세포를 유도하는 방법 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016186346A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112513257A (zh) * | 2018-06-14 | 2021-03-16 | 中央研究院 | 产生诱导式少突胶质谱系细胞的方法及使用所述细胞的治疗 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101357402B1 (ko) * | 2012-01-20 | 2014-02-07 | 주식회사 스템랩 | 유전자 도입 없이 직접적 역분화를 통해 체세포로부터 신경상피세포 및 신경줄기세포를 유도하는 방법 |
-
2016
- 2016-05-02 WO PCT/KR2016/004603 patent/WO2016186346A1/ko active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101357402B1 (ko) * | 2012-01-20 | 2014-02-07 | 주식회사 스템랩 | 유전자 도입 없이 직접적 역분화를 통해 체세포로부터 신경상피세포 및 신경줄기세포를 유도하는 방법 |
Non-Patent Citations (5)
Title |
---|
KERR, BRADLEY J. ET AL.: "Leukemia Inhibitory Factor Promotes Oligodendrocyte Survival after Spinal Cord Injury", GLIA, vol. 51, no. 1, 2005, pages 73 - 79, XP055335506 * |
KIM, JANG HWAN ET AL.: "Direct Reprogramming of Mouse Fibroblasts to Neural Progenitors", PNAS, vol. 108, no. 19, 2011, pages 7838 - 7843, XP055027748 * |
NAJM, FADI J. ET AL.: "Transcription Factor-Mediated Reprogramming of Fibroblasts to Expandable, Myelinogenic Oligodendrocyte Progenitor Cells", NATURE BIOTECHNOLOGY, vol. 31, no. 5, 2013, pages 426 - 433, XP055106732 * |
PEDRAZA, CARLOS E. ET AL.: "Induction of Oligodendrocyte Differentiation and In Vitro Myelination by Inhibition of Rho-Associated Kinase", ASN NEURO, vol. 6, no. 4, 2014, pages 1 - 17, XP055167426 * |
See also references of EP3321354A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112513257A (zh) * | 2018-06-14 | 2021-03-16 | 中央研究院 | 产生诱导式少突胶质谱系细胞的方法及使用所述细胞的治疗 |
EP3807402A4 (en) * | 2018-06-14 | 2022-04-27 | Academia Sinica | METHOD FOR GENERATE INDUCED OLIGODENDROCYTE LINEAGE CELLS AND TREATMENT USING SUCH CELLS |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7407865B2 (ja) | 細胞の再プログラミングのための方法とその用途 | |
US11572540B2 (en) | Method for inducing oligodendrocyte precursor cells from OCT4-induced human somatic cells through direct reprogramming | |
EP2982747B1 (en) | Method for producing reprogrammed derivative neuronal stem cell from non-neuronal cell by using hmga2 | |
CA2455580C (en) | Multipotent stem cells from peripheral tissues and uses thereof | |
Kim | Stem cell potential in Parkinson's disease and molecular factors for the generation of dopamine neurons | |
Flitsch et al. | Transcription factor-based fate specification and forward programming for neural regeneration | |
Trawczynski et al. | Restoring motor neurons in spinal cord injury with induced pluripotent stem cells | |
Kunisada et al. | The stemness of neural crest cells and their derivatives | |
El Ayachi et al. | Human dental stem cell derived transgene‐free iPSCs generate functional neurons via embryoid body‐mediated and direct induction methods | |
Dwivedi et al. | Therapeutical growth in oligodendroglial fate induction via transdifferentiation of stem cells for neuroregenerative therapy | |
WO2016032151A1 (ko) | 콜린성 신경세포의 생산방법 | |
WO2016186346A1 (ko) | Oct4가 도입된 인간체세포로부터 직접적 리프로그래밍을 통한 희소돌기아교 전구세포를 유도하는 방법 | |
KR20110124106A (ko) | Shh, FGFR 티로신 키나아제 억제제, MEK 억제제와 GSK 억제제를 이용하여 체세포로부터 배아줄기세포 유사세포로의 역분화를 유도하는 조성물 및 이를 이용한 배아줄기세포 유사세포의 제조방법 | |
Pouya et al. | SOX2 protein transduction directly converts human fibroblasts into oligodendrocyte-like cells | |
WO2019117454A1 (ko) | 세포 소기관 스트레스 조절 인자를 이용하는 고효율 세포전환용 배지 첨가제 | |
Adeeb et al. | Stem cell therapy for spinal cord injury: The use of oligodendrocytes and motor neurons derived from human embryonic stem cells | |
Raciti | Reprogramming fibroblasts to Neural-Stem-like cells by structured overexpression of pallial patterning genes | |
Wenbin et al. | Direct Conversion of Cord Blood CD34+ Cells Into Neural Stem Cells by OCT4 | |
Li et al. | Characterization of glial-restricted precursors from rhesus monkey embryonic stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16796673 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017560793 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2986368 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15575369 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2016264166 Country of ref document: AU Date of ref document: 20160502 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016796673 Country of ref document: EP |